| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e04a9c30b01a6909696dc92e883f241c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2007-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba983b3bcf21012d71ad0ee70e9557a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62d641128fda9109a115e4ebee63718a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28c367333651595647c1c8d97ad4ae9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8020566bca277eea108a713f23fbdb2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a9bf81c94bddf5b833973a1c56f5ccd |
| publicationDate |
2009-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2062596-A1 |
| titleOfInvention |
Anti-tumor agent |
| abstract |
Therapeutic agents for removal of CD10-expressing cells from the bodies of patients are expected to be useful as therapeutic agents for various cancers such as lymphoma and leukemia in which CD 10 is expressed and for inflammatory diseases mediated by the cells in which CD10 is expressed (B cells and neutrophils). However, there is a problem that patients continuously administered with an anti-tumor agent comprising an anti-CD20 antibody as an active ingredient become resistant to the anti-tumor agent comprising the anti-CD20 antibody as an active ingredient whereby the therapeutic effect lowers. The present invention provides an agent which is effective to a patient who is administered by an agent comprising anti-CD20 antibody as an active ingredient. |
| priorityDate |
2006-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |